We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NTRA & Aveta Partner to Advance MRD-Guided Trial in Head & Neck Cancer
Read MoreHide Full Article
Key Takeaways
Natera partnered with Aveta to integrate Signatera into a global Phase 3 LA-HNSCC trial.
Signatera will assess MRD and treatment response across neoadjuvant to follow-up care.
The trial may enroll 826 patients globally, with enrollment expected in the second half of 2026.
Natera (NTRA - Free Report) recently announced a partnership with Aveta Biomics to support AVTA 30-01, a global Phase 3 registrational trial of its oral immunotherapy, APG-157, in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Natera’s Signatera test will be integrated into the AVTA 30-01 Phase 3 study to assess molecular residual disease (MRD) and treatment response during neoadjuvant, induction, adjuvant and follow-up care.
Management noted that growing clinical evidence continues to demonstrate the value of Signatera for MRD detection in head and neck cancer. The company believes its collaboration with Aveta on the AVTA 30-01 trial will further demonstrate Signatera’s potential to advance the field and improve patient care.
Likely Trend of NTRA Stock Following the News
Shares of NTRA have lost 0.3% since the announcement on Monday. Year to date, the stock has gained 18.5% against the industry’s 2.3% decline. The S&P 500 has risen 9.7% in the same timeframe.
The partnership with Aveta Biomics is a positive development for Natera as it expands the clinical use of Signatera in a global Phase 3 registrational trial. Successful validation of Signatera for MRD monitoring and treatment response in head and neck cancer could strengthen its clinical evidence and support wider adoption. Over time, the collaboration could enhance Natera’s position in precision oncology while creating opportunities for biopharma partnerships centered on MRD-guided treatment strategies.
NTRA currently has a market capitalization of $39.00 billion.
Image Source: Zacks Investment Research
More on the News
APG-157 is Aveta’s first-in-class oral immunotherapy designed to benefit both immune-hot and immune-cold tumors in LA-HNSCC. The therapy has received FDA Fast Track and Orphan Drug Designations for this indication. The Phase 3 study builds on Phase 2 results that demonstrated favorable safety, evidence of tumor control, deep molecular responses and promising event-free survival outcomes.
The trial is expected to enroll approximately 826 patients across North America, Europe, Asia-Pacific and Australia, with patient enrollment to begin in the second half of 2026. It will include separate randomized cohorts for patients with resectable and unresectable locally advanced disease, with both treatment and control arms. Signatera will serve as a secondary endpoint to generate insights into disease recurrence and therapeutic response through circulating tumor DNA (ctDNA) monitoring to assess MRD.
Head and neck cancer affects roughly 950,000 people worldwide each year, and recurrence remains a significant cause of mortality despite advances in surgery, radiation and immunotherapy. This collaboration further expands Natera’s clinical evidence in head and neck cancer, following the positive results from the recently concluded Phase 2 SINERGY trial, which supported the use of Signatera MRD-guided monitoring in this disease setting.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the minimal residual disease testing market was valued at $1.70 billion in 2025 and is expected to witness a CAGR of 12% through 2034.
Factors like the demand for highly sensitive technologies like next-generation sequencing and digital PCR, which accurately detect minimal residual cancer cells to guide treatment decisions and predict patient outcomes, are boosting the market’s growth.
Other News
Natera recently announced a collaboration with CytoDyn to evaluate ctDNA dynamics and generate real-world molecular data in support of the latter’s metastatic colorectal cancer (mCRC) program.
In May, Natera announced a collaboration with Diakonos Oncology to incorporate its Signatera molecular residual disease test into Diakonos’ DOC-RM Phase I/II investigational immunotherapy trial for patients with refractory melanoma.
Natera received the FDA approval of Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab immunotherapy in patients with muscle-invasive bladder cancer.
Some better-ranked stocks from the broader medical space are BrightSpring Health (BTSG - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .
BrightSpring Health, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 adjusted earnings per share (EPS) of 39 cents, which beat the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion surpassed the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
BrightSpring Health has an estimated long-term earnings growth rate of 46.5%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 14.6%.
Globus Medical, currently carrying a Zacks Rank #2, reported a first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
View the Zacks #1 Rank List
Image: Bigstock
NTRA & Aveta Partner to Advance MRD-Guided Trial in Head & Neck Cancer
Key Takeaways
Natera (NTRA - Free Report) recently announced a partnership with Aveta Biomics to support AVTA 30-01, a global Phase 3 registrational trial of its oral immunotherapy, APG-157, in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Natera’s Signatera test will be integrated into the AVTA 30-01 Phase 3 study to assess molecular residual disease (MRD) and treatment response during neoadjuvant, induction, adjuvant and follow-up care.
Management noted that growing clinical evidence continues to demonstrate the value of Signatera for MRD detection in head and neck cancer. The company believes its collaboration with Aveta on the AVTA 30-01 trial will further demonstrate Signatera’s potential to advance the field and improve patient care.
Likely Trend of NTRA Stock Following the News
Shares of NTRA have lost 0.3% since the announcement on Monday. Year to date, the stock has gained 18.5% against the industry’s 2.3% decline. The S&P 500 has risen 9.7% in the same timeframe.
The partnership with Aveta Biomics is a positive development for Natera as it expands the clinical use of Signatera in a global Phase 3 registrational trial. Successful validation of Signatera for MRD monitoring and treatment response in head and neck cancer could strengthen its clinical evidence and support wider adoption. Over time, the collaboration could enhance Natera’s position in precision oncology while creating opportunities for biopharma partnerships centered on MRD-guided treatment strategies.
NTRA currently has a market capitalization of $39.00 billion.
Image Source: Zacks Investment Research
More on the News
APG-157 is Aveta’s first-in-class oral immunotherapy designed to benefit both immune-hot and immune-cold tumors in LA-HNSCC. The therapy has received FDA Fast Track and Orphan Drug Designations for this indication. The Phase 3 study builds on Phase 2 results that demonstrated favorable safety, evidence of tumor control, deep molecular responses and promising event-free survival outcomes.
The trial is expected to enroll approximately 826 patients across North America, Europe, Asia-Pacific and Australia, with patient enrollment to begin in the second half of 2026. It will include separate randomized cohorts for patients with resectable and unresectable locally advanced disease, with both treatment and control arms. Signatera will serve as a secondary endpoint to generate insights into disease recurrence and therapeutic response through circulating tumor DNA (ctDNA) monitoring to assess MRD.
Head and neck cancer affects roughly 950,000 people worldwide each year, and recurrence remains a significant cause of mortality despite advances in surgery, radiation and immunotherapy. This collaboration further expands Natera’s clinical evidence in head and neck cancer, following the positive results from the recently concluded Phase 2 SINERGY trial, which supported the use of Signatera MRD-guided monitoring in this disease setting.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the minimal residual disease testing market was valued at $1.70 billion in 2025 and is expected to witness a CAGR of 12% through 2034.
Factors like the demand for highly sensitive technologies like next-generation sequencing and digital PCR, which accurately detect minimal residual cancer cells to guide treatment decisions and predict patient outcomes, are boosting the market’s growth.
Other News
Natera recently announced a collaboration with CytoDyn to evaluate ctDNA dynamics and generate real-world molecular data in support of the latter’s metastatic colorectal cancer (mCRC) program.
In May, Natera announced a collaboration with Diakonos Oncology to incorporate its Signatera molecular residual disease test into Diakonos’ DOC-RM Phase I/II investigational immunotherapy trial for patients with refractory melanoma.
Natera received the FDA approval of Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab immunotherapy in patients with muscle-invasive bladder cancer.
Natera, Inc. Price
Natera, Inc. price | Natera, Inc. Quote
NTRA’s Zacks Rank & Key Picks
Natera currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are BrightSpring Health (BTSG - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .
BrightSpring Health, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 adjusted earnings per share (EPS) of 39 cents, which beat the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion surpassed the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
BrightSpring Health has an estimated long-term earnings growth rate of 46.5%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 14.6%.
Globus Medical, currently carrying a Zacks Rank #2, reported a first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.